EcoR1 Capital

EcoR1 Capital is a San Francisco-based venture capital company that also offers investment management services. It is named after the restriction enzyme of the same name that led to major advances in the biomedical field. It states that it focuses on biomedical companies that are developing treatments for untreated diseases.

The firm invests in both early and late-stage funding rounds for its portfolio companies. It has made more than 41 investments and has had 24 exits. EcoR1 Capital raised three funds between 2017 and 2019, totaling more than $400 million.